January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

Investing.com -- The Federal Trade Commission (FTC) has released a report showing that the three largest pharmacy benefit managers (PBMs) in the industry have significantly marked up prices on ...

consumer or employer and forbid a PBM from paying a reimbursement less than the national average drug acquisition cost, plus a professional dispensing fee. The legislation mandates that contracts ...

Requiring a patient to use an in-network pharmacy. Paying a pharmacy an amount less than the national average drug acquisition cost for the drug dispensed. The bill could require a PBM to provide ...

4. NADAC (National Average Drug Acquisition Cost) volatility: Fluctuations in drug acquisition costs present ongoing challenges for pricing and margins. These factors have contributed to Cencora's ...

4. NADAC (National Average Drug Acquisition Cost) volatility: Fluctuations in drug acquisition costs present ongoing challenges for pricing and margins. These factors have contributed to Cencora's ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

METHODS: National STD guidelines, purchasing mechanisms, and drug acquisition costs from 15 countries were compiled, using information from ministries of health and European Commissions headquarters.

Despite the uncertainty, Woods clarifies that what's happening now is not unprecedented, noting that "10% corrections happen, on average ... Financial and Lincoln National have been highlighted ...

Ensuring fair and adequate Medicaid managed care pharmacy reimbursement from PBMs to cover the cost to acquire and dispense prescription drugs. - Requiring National Average Drug Acquisition Cost ...

Bivalirudin resulted in an average drug acquisition cost savings of $402 per patient (as treated) compared with UFH plus glycoprotein IIb/IIIa inhibitors. Treatment with bivalirudin also resulted ...